Key result
Bromocriptine therapy for 1 week reduced plasma norepinephrine by 40% to 50% (p<0.05) and lowered blood pressure in patients with primary hypertension.
Why the study?
Does bromocriptine reduce blood pressure and sympathetic activity in patients with primary hypertension?
Population
7 patients with primary hypertension, mean age 29 ± 3 years
Comparison
Bromocriptine vs Respective placebo periods
Design
Other
Follow-up
1 week
Authors
Loading...
Supports dopaminergic pathways in hypertension pathogenesis; hypothesis-generating and requires larger trials before clinical consideration.
RCT (n=7)
Does bromocriptine reduce blood pressure and sympathetic activity in patients with primary hypertension?
p-value: p=< 0.05
Bromocriptine reduces sympathetic outflow and blood pressure in primary hypertension, suggesting that reduced central dopaminergic activity may contribute to the condition.
Kolloch et al. (1980) conducted an RCT in Primary hypertension (n=7). Bromocriptine vs. Placebo was evaluated on Plasma norepinephrine (NE) levels (p=< 0.05). Bromocriptine therapy for 1 week reduced plasma norepinephrine by 40% to 50% (p<0.05) and lowered blood pressure in patients with primary hypertension.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: